Hetrombopag

Hetrombopag is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist; specifically stimulates proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways; specifically enhances the viability and promoted the growth of 32D-MPL cells in hollow fibres implanted in nude mice, exhibiting much higher potency than eltrombopag in vivo. Other Indication Phase 2 Clinical

References 1. Zhou N, et al. Cardiovasc Drugs Ther. 2016 Dec;30(6):567-577. 2. Xie C, et al. J Cell Mol Med. 2018 Nov;22(11):5367-5377. View Related Products by Target Thrombopoietin Receptor (CD110) Other Indication